PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28373843-8	2017	Results: ddC treatment resulted in thermal hyperalgesia and increased transcripts of the synthesizing enzyme Plcbeta1 and decreased Daglbeta in the paw skins, but not Napepld, and Daglalpha compared to vehicle treatment.	Zalcitabine	9-12	phospholipase C, beta 1	Mus musculus	109-117	
28373843-8	2017	Results: ddC treatment resulted in thermal hyperalgesia and increased transcripts of the synthesizing enzyme Plcbeta1 and decreased Daglbeta in the paw skins, but not Napepld, and Daglalpha compared to vehicle treatment.	Zalcitabine	9-12	diacylglycerol lipase, beta	Mus musculus	132-140	
28373843-8	2017	Results: ddC treatment resulted in thermal hyperalgesia and increased transcripts of the synthesizing enzyme Plcbeta1 and decreased Daglbeta in the paw skins, but not Napepld, and Daglalpha compared to vehicle treatment.	Zalcitabine	9-12	diacylglycerol lipase, alpha	Mus musculus	180-189	
28373843-9	2017	Transcripts of the inactivating enzymes Faah and Mgll were downregulated in the brain and/or paw skin but not in the spinal cord of ddC-treated mice.	Zalcitabine	132-135	fatty acid amide hydrolase	Mus musculus	40-44	
28373843-9	2017	Transcripts of the inactivating enzymes Faah and Mgll were downregulated in the brain and/or paw skin but not in the spinal cord of ddC-treated mice.	Zalcitabine	132-135	monoglyceride lipase	Mus musculus	49-53	
28373843-13	2017	The endocannabinoids AEA and 2-AG have antihyperalgesic activity, which is dependent on cannabinoid receptor and GPR55 activation.	aea	21-24	G protein-coupled receptor 55	Mus musculus	113-118	
28373843-13	2017	The endocannabinoids AEA and 2-AG have antihyperalgesic activity, which is dependent on cannabinoid receptor and GPR55 activation.	glyceryl 2-arachidonate	29-33	G protein-coupled receptor 55	Mus musculus	113-118